No Data
ysb (09885.HK) granted 1.86 million shares of bonus shares.
On November 6, Gronghui announced that ysb (09885.HK) issued 1.86 million bonus shares to the grantees under the stock incentive plan in 2024, accounting for approximately 0.29% of the total number of issued shares as of the date of this announcement. The reason for granting the bonus is to provide incentives for the grantees to strive for the success of the company and its affiliates, reward their unremitting efforts, and provide a way for them to benefit from the appreciation of shares by granting bonus shares.
YSB Set to Acquire Folding Space (Cayman) for 1.03 Billion Yuan, Changes Use of Proceeds From Global Offering
HK stocks surge | ysb (09885) opens over 5% higher, planning to acquire a pharmaceutical block with issued and outstanding shares totaling 1.035 billion yuan 100%
YSB (09885) opened more than 5% higher, as of the time of publication, it rose by 5.43%, closing at 7.76 Hong Kong dollars, with a turnover of 0.4982 million Hong Kong dollars.
YSB (09885) completed a full acquisition of a pharmaceutical company for 1.035 billion, accelerating the layout of its own brand business.
On October 15, 2024, YSB (09885) announced on the HKEX website that it has signed a trading agreement to acquire 100% equity of csi health care 100 index. The total consideration for the acquisition is RMB 1.035 billion, with a cash consideration of RMB 0.42 billion, and a stock consideration of RMB 0.615 billion.
YSB (09885.HK) cash plus new shares fully subscribed Hunan space folding, involving more than 1 billion RMB.
YSB (09885.HK) announced the acquisition of 100% equity of Hunan Spatial Fold, an independent third party, to acquire pharmaceutical supply chain, operation service platform, and related businesses. Through merging two customer networks, it aims to achieve mutual penetration and complementary advantages. The total consideration is 1.035 billion RMB, including 0.42 billion RMB in cash; and up to 56.2918 million shares issued as consideration shares, accounting for 8.74% of the expanded capital. The issue price is 12 RMB, a premium of 63.04% over the previous trading day (15th).
Each share of ysb has a premium of 63.04%, with a total acquisition of 1.035 billion in cash and new shares, fully acquiring "One Drug".
On October 15th, YSB (09885) announced on the HKEX that it has signed a trade agreement to acquire 100% of the shares of the csi health care 100 index, with a total consideration of RMB 1.035 billion, including a cash consideration of 0.42 billion yuan and a share consideration of 0.615 billion yuan. The share consideration part will issue new shares to the original shareholder of the csi health care 100 index at HKD 12 per share, with a premium of 63.04% over the closing price on the day of the signing of the acquisition agreement. This acquisition is a key step for YSB to deepen its industry layout, further enhancing its market competitiveness and profitability. The csi health care 100 index was established in 2019 and is a leading domestic
No Data
No Data